<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251113067980N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-26</date_registration>
      <primary_sponsor>University of Tehran</primary_sponsor>
      <public_title>The effect of exercise on SMA type 3 patients.</public_title>
      <acronym></acronym>
      <scientific_title>Safety, feasibility, and impact of ten weeks of supervised progressive resistance training of lower limbs on select functional, biomechanical, and blood biomarker factors in ambulatory adults with SMA type 3 and quality of life.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-12-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87530</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To ensure age homogeneity within the study population, participants will be categorized into two age groups (18-29 years and 30+) and randomly assigned to either the control or intervention group using a manual lottery-based randomization method, ensuring a balanced age distribution for subsequent analyses.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Spinal Muscular Atrophy Type 3.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: Progressive resistance exercises for the lower extremities in closed and open kinetic chains, supervised and for the first five weeks, twice a week, and for the second five weeks, three times a week, and individually at a specific time for each person, with a trainer-to-trainee ratio of two to one. Intervention 2: Control group: No intervention will be administered to the control group, and participants will continue their usual daily activities without restriction. Should the intervention prove effective and be confirmed by a specialist physician, the same protocol implemented in the research group will be offered under identical conditions and at the same location to members of the control group, on a voluntary basis and according to each participant’s preference. It should be noted that, for those control group participants who wish to receive the intervention after completion of the study, these services will be provided free of charge.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The decision regarding the sharing of individual participant data (IPD) has not yet been finalized. The research team will evaluate the feasibility, ethical considerations, and institutional policies related to IPD sharing after study completion. Any future plan for data sharing will be aligned with participant consent and applicable regulations.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahram Khorshidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Sport Sciences and Health, University of Tehran, North Campus (Pardis-e Shomali), North Kargar Street, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1439813117</zip>
        <telephone>+98 21 8835 1730</telephone>
        <email>shahram.khorshidi@ut.ac.ir</email>
        <affiliation>Faculty of Sport Sciences and Health, University of Tehran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Khadijeh Sohrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Sport Sciences and Health, University of Tehran, North Campus (Pardis-e Shomali), North Kargar Street, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1439813117</zip>
        <telephone>+98 21 8835 1730</telephone>
        <email>khadije.sohrabi@ut.ac.ir</email>
        <affiliation>Faculty of Sport Sciences and Health, University of Tehran</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age ≥18 years.
Homozygous deletion of exon 7 of the SMN1 gene, confirmed by a test report and a specialist physician, indicating SMA type 3
Ability to walk independently for at least 25 meters
informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of surgery or fracture in the past six months
Moderate or severe scoliosis
Serum creatine kinase (CK) levels of participants above 1000 units per liter in the past three months
Non-ambulatory
Under the age of eighteen years
The presence of any concurrent chronic diseases such as diabetes, cardiovascular diseases, kidney disease, etc.
Any type of SMA other than type 3</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G12.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other inherited spinal muscular atrophy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: Progressive resistance exercises for the lower extremities in closed and open kinetic chains, supervised and for the first five weeks, twice a week, and for the second five weeks, three times a week, and individually at a specific time for each person, with a trainer-to-trainee ratio of two to one</i_keyword>
      <i_keyword>Control group: No intervention will be administered to the control group, and participants will continue their usual daily activities without restriction. Should the intervention prove effective and be confirmed by a specialist physician, the same protocol implemented in the research group will be offered under identical conditions and at the same location to members of the control group, on a voluntary basis and according to each participant’s preference. It should be noted that, for those control group participants who wish to receive the intervention after completion of the study, these services will be provided free of charge.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Muscular strength, referring to maximum voluntary isometric contraction; Function, referring to the Timed Up and Go (TUG) test, the Six-Minute Walk Test (6MWT), and the Hammersmith Functional Motor Scale Expanded (HFMSE); Quality of Life Questionnaire; Blood Biomarkers including Interleukin 6, Interferon Gamma, Tumor Necrosis Factor Alpha. Timepoint: Measurement time points will be at the beginning of the study (before the start of the intervention) and at the end of the study. Method of measurement: Handheld dynamometer for muscle strength and for functional tests according to instructions. For quality of life, the SF-36 questionnaire, and for blood biomarkers, the ELISA method and the Zellbio Germany kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Static balance, spatial and temporal gait parameters, dorsiflexion and plantar flexion angle, blood creatine kinase level, fatigue score. Timepoint: All variables at the beginning and end of the intervention were only creatine kinase levels at the beginning of the study, week 5, and at the end of the intervention. Method of measurement: For static balance, use a force plate; for spatiotemporal gait parameters, use a camera with a frame rate of 60 Hz; for dorsiflexion and plantar flexion angles, use a goniometer; for creatine kinase levels, use the ELISA method; for fatigue, use the Fatigue Severity Scale (FSS) questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Tehran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-20</approval_date>
        <contact_name>Ethics Committee in Research, Faculty of Physical Education and Sport Sciences, University of Tehran</contact_name>
        <contact_address>culty of Physical Education and Sport Sciences, University of Tehran, North Kargar Street, Central Campus, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
